Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
Conditions
B-Cell Non-Hodgkin Lymphoma · Burkitt Lymphoma · Diffuse Large B-Cell Lymphoma, Not Otherwise Specified · EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified · High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements · High Grade B-Cell Lymphoma, Not Otherwise Specified · Primary Mediastinal Large B-Cell Lymphoma · T-Cell/Histiocyte-Rich Large B-Cell Lymphoma · Transformed B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma to Diffuse Large B-Ce
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Contact: Principal Investigator (Mengyang Di, MD, PhD)
Study leads
Mengyang Di, MD, PhD
Principal Investigator
Fred Hutch/University of Washington Cancer Consortium